Evidence map›Paper›PMID 26457030›Full record

Observational studyWorld journal of gastroenterology2015

Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.

Liliana Belgioia, Stefano Vagge, Dario Agnese, Stefania Garelli, Roberto Murialdo, Giuseppe Fornarini, Silvana Chiara, Fabio Gallo, Almalina Bacigalupo, Renzo Corvò

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT).Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Liliana BelgioiaLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Stefano VaggeLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Dario AgneseLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Stefania GarelliLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Roberto MurialdoLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Giuseppe FornariniLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Silvana ChiaraLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Fabio GalloLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Almalina BacigalupoLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
Renzo CorvòLiliana Belgioia, Stefano Vagge, Dario Agnese, Almalina Bacigalupo, Renzo Corvò, Department of Radiation Oncology, AOU IRCCS San Martino - IST National Cancer Research Institute and University, 16132 Genoa, Italy.
National Cancer Research Institute · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the toxicity and response of intensity-modulated radiotherapy schedule intensified with a simultaneous integrated boost in anal canal cancer.

methodsFrom March 2009 to March 2014, we retrospectively analyzed 41 consecutive patients treated with intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy for anal canal squamous cell carcinoma at our center. Radiotherapy was delivered via simultaneous integrated boost (SIB) technique by helical tomotherapy, and doses were adapted to two clinical target volumes according to the tumor-node-metastasis (TNM) stage: 50.6 Gy and 41.4 Gy in 23 fractions in T1N0, 52.8 Gy and 43.2 Gy in 24 fractions in T2N0, and 55 Gy and 45 Gy in 25 fractions in all patients with N positive and/or ≥ T3, respectively, to planning target volumes 1 and 2. The most common chemotherapy regimen was 5-fluorouracil and mitomycin-based. Human papilloma virus (HPV) p16 expression was performed by immunohistochemistry and evaluated in the majority of patients. Acute and late toxicity was scored according to CTCAe v 3.0 and RTOG scales.

resultsThe median follow-up was 30 mo (range: 12-71). Median age was 63 years (range 32-84). The stage of disease was: stage I in 2 patients, stage II in 13 patients, stage IIIA in 12 patients, and stage IIIB in 14 patients, respectively. Two patients were known to be HIV positive (4.9%). HPV p16 expression status was positive in 29/34 (85.3%) patients. The 4-year progression-free survival and overall survival in HPV-positive patients were 78% and 92%, respectively. Acute grade 3 skin and gastrointestinal toxicities were reported in 5% and 7.3% of patients, respectively; patients' compliance to the treatment was good due to a low occurrence of severe acute toxicity, although treatment interruptions due to toxicity were required in 7.3% of patients. At 6 mo from end of treatment, 36/40 (90%) patients obtained complete response; during follow-up, 5 (13.8%) patients presented with disease progression (local or systemic).

conclusionIn our experience, intensified SIB-IMRT with chemotherapy is very feasible in clinical practice, with excellent results in terms of overall survival and local control.

Indexed as

AdultAgedAged, 80 and overAnus NeoplasmsCarcinoma, Squamous CellChemoradiotherapyCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleFluorouracilFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMitomycinCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16FluorouracilMitomycinNeoplasm ProteinsAnal canal cancerHelical tomotherapyHPVIntensity-modulated radiotherapySimultaneous integrated boost

Identifiers

PMID26457030
PMCPMC4588092
OpenAlexW1836002472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.